The Effectiveness of Complex Treatment of Ulcerative Colitis in Integrative Medicine

Year 2023, , 11 - 21, 26.06.2023

Arzu Guliyeva , Gulnar Guliyeva

https://doi.org/10.35206/jan.1319777

Abstract

The aim of the study was to develop a new complex treatment of ulcerative colitis using integrative medicine methods. The study was conducted on 16 patients with ulcerative colitis with total (8 patients) and left-sided lesions (8 patients). The progress of the disease was traced on the basis of complaints, levels of fecal calprotectin and lactoferrin, ESR and endoscopic picture of the colon mucosa. Depending on the severity and individual characteristics of the progress of the disease, the treatment lasted 2-8 months. The treatment was carried out against the background of taking mesalazine in two stages. At the first stage (1-3 weeks), treatment was carried out to eliminate the causes of the leaky gut syndrome (use of antiparasitic, antibacterial, antiprotozoal drugs) and restore the microbiota (use of eubiotics and short-chain fatty acids). The aim of the second stage of treatment (4-6 weeks) was immunomodulation and regeneration of the intestinal mucosa (the use of bioregulatory, isopathic, orthomolecular drugs and interleukin preparations). Patients received drugs orally, in the form of intravenous infusions and local injections into the metameric zones and acupuncture points of the large intestine. Also, in parallel, neural therapy was carried out with procaine at the points of the large intestine. The results obtained showed a significant decrease in calprotectin, lactoferrin and an improvement in the endoscopic picture of the large intestine. Colonoscopy showed complete recovery in group I in 2, and in group II in 3 patients, in other cases was noted 70% recovery of the mucous membrane. Thus, the use of a complex of integrative medicine methods with the use of safe bioregulatory drugs makes it possible to obtain high efficiency in the treatment of ulcerative colitis.

Keywords

Integrative medicine, Ulcerative colitis, Complex treatment

Tamamlayıcı Tıpta Kompleks Ülseratif Kolit Tedavisinin Etkinliği

Abstract

Bu çalışmanın amacı bütünleyici tıp metotlarını kullanarak ülseratif kolit için yeni bir kompleks tedavi geliştirilmesidir. Çalışma tüm kolonu tutan ülseratif kolitli 8 hasta, sol kolunu tutan 8 hasta olmak üzere toplam 16 hasta üzerinde yapıldı. Hastalıktaki ilerleme şikayetler, fekal kalprotektin ve laktoferrin düzeyleri, ESR ve kolon mukozasının endoskopik incelenmesi temelinde izlendi. Hastalığın ilerlemesinin ciddiyetine ve bireysel özelliklere göre tedavi 2-8 ay sürmüştür. Tedavi iki aşamalı mesalazin alımına karşı gerçekleştirildi. İlk aşamada (1-3 hafta) geçirgen bağırsak sendromunun nedenlerini ortadan kaldırmak (antiparaziter, antibakteriyel, antiprotozoal ilaç kullanımı) ve mikrobiyotayı yeniden yapılandırmak için (öbiyotiklerin ve kısa zincirli yağ asitlerinin kullanımı) uygulandı. Tedavinin ikinci aşamasının amacı ise (4-6 hafta) immünomodülasyon ve bağırsak mukozasının yenilenmesiydi (biyoregülatör, izopatik, ortomoleküler ilaç ve interlökin preparatlarının kullanımı ile). Hastalar kalın bağırsağın metamerik bölgelerine ve akupunktur noktalarına intravenöz infüzyonlar ve lokal enjeksiyonlar şeklinde oral yoldan ilaç aldılar. Ayrıca kalın bağırsağa prokain ile nöral terapi yapıldı. Kalprotektin, laktoferrin düzeylerinde anlamlı bir azalma ve endoskopik tabloda bir iyileşme sağlandı. Kolonoskopide grup 1’deki 2 hastada ve grup 2’deki 3 hastada tam iyileşme görüldü diğer vakalarda ise mukozada %70 iyileşme belirlendi. Güvenli biyoregülasyon ilaçlarının kullanımı ve tamamlayıcı tıp metotlarının kompleks kullanımı ile ülseratif kolit tedavisinde yüksek verimlilik elde edilmesini mümkün kılmıştır.

References

• Asakura, K., Nishiwaki, Y., Inoue, N., Hibi, T., Watanabe, M., & Takebayashi, T. (2009). Prevalence of ulcerative colitis and Crohn’s disease in Japan. Journal of Gastroenterology, 44, 659-665.
• Feuerstein J. D., Moss A. C., & Farraye F. A. (2019). Ulcerative Colitis. Mayo Clinic Proceedings, 94,1357-1373.
• Hirten, R. P., & Sands, B. E. (2021). New therapeutics for ulcerative colitis. Annual Review of Medicine, 72, 199-213.
• Hirten, R. P., Iacucci, M., Shah, S., Ghosh, S., & Colombel, J. F. (2018). Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clinical Gastroenterology and Hepatology, 16, 1374-1384.
• Jones, G. R., Lyons, M., Plevris, N., Jenkinson, P. W., Bisset, C., Burgess, C., ... & Lees, C. W. (2019). IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut, 68, 1953-1960.
• Lamb C. A., Kennedy N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., …& Hawthorne, A. B. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68, 101-106.
• Mao, R., & Hu, P. J. (2016). The future of IBD therapy: where are we and where should we go next?. Digestive Diseases, 34, 175-179.
• Ordás I., Eckmann L., Talamini M., Baumgart D., & Sandborn W. (2012). Ulcerative colitis. Lancet, 380,1606-1619.
• Pasvol, T. J., Horsfall, L., Bloom, S., Segal, A. W., Sabin, C., Field, N., & Rait, G. (2020). Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open, 10, e036584.
• Peyrin‐Biroulet, L., & Lémann, M. (2011). remission rates achievable by current therapies for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 33, 870-879.
• Sandborn, W. J., Panés, J., Sands, B. E., Reinisch, W., Su, C., Lawendy, N., ... & Danese, S. (2019). Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Alimentary Pharmacology & Therapeutics, 50, 1068-1076.
• Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., ... & Panés, J. (2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 376, 1723-1736.
• Sands, B. E., Sandborn, W. J., Panaccione, R., O’Brien, C. D., Zhang, H., Johanns, J., ... & Marano, C. (2019). Ustekinumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 381, 1201-1214.
• Sands, B. E., Taub, P. R., Armuzzi, A., Friedman, G. S., Moscariello, M., Lawendy, N., ... & Feagan, B. G. (2020). Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clinical Gastroenterology and Hepatology, 18, 123-132.
• Segal, J. P., LeBlanc, J. F., & Hart, A. L. (2021). Ulcerative colitis: an update. Clinical Medicine, 21, 135.
• Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., ... & Warren, B. F. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology, 19, 5A-36A.
• Sun, Y., Zhang, Z., Zheng, C. Q., & Sang, L. X. (2021). Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review. World Journal of Gastroenterology, 27, 2963-2978.
• Ungaro, R., Mehandru, S., Allen, P., Peyrin-Biroulet, L., & Colombel, J-F. (2017). Ulcerative colitis. Lancet, 389, 1756-1770.
• Vermeire, S., O'Byrne, S., Keir, M., Williams, M., Lu, T. T., Mansfield, J. C., ... & Rutgeerts, P. (2014). Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. The Lancet, 384, 309-318.
• Vermeire, S., Sandborn, W. J., Danese, S., Hébuterne, X., Salzberg, B. A., Klopocka, M., ... & Reinisch, W. (2017). Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet, 390, 135-144.